Prostate cancer screening: More harm than good?

American Family Physician

Volumn 58, Issue 2, 1998, Pages 432-438

  Lefevre, Michael L ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CONSERVATIVE TREATMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; IMPOTENCE; MALE; PROSTATE CANCER; PROSTATECTOMY; URINE INCONTINENCE;

AGE DISTRIBUTION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0031857280     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Smith DS, Bullock AD, Catalona WJ, Herschman JD. Racial differences in a prostate cancer screening study. J Urol 1996;156:1366-9.
2. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276:615-9.
3. Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997;278:44-6.
4. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2d ed. Baltimore: Williams & Wilkins, 1996.
5. Surveillance, Epidemiology, and End Results (SEER) Program public use CD-ROM (1973-94), National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch. Released May 1997, based on the August 1996 submission.
6. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273: 289-94.
7. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990; 36:493-8.
8. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
9. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51 [published erratum in JAMA 1997;278:118].
10. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71 [published erratum in JAMA 1997;278:206].
11. Mark DH. Mortality of patients after radical prostatectomy: analysis of recent Medicare claims. J Urol 1994;152:896-8.
12. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995;45:1007-15.
13. Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA 1996;276:1976-9.
14. American Academy of Family Physicians. AAFP reference manual, 1997-1998. Kansas City, Mo.: American Academy of Family Physicians, 1998: Appendix F - periodic health examination:62.